Ignite Creation Date:
2025-12-25 @ 3:49 AM
Ignite Modification Date:
2025-12-26 @ 2:37 AM
Study NCT ID:
NCT01454102
Status:
COMPLETED
Last Update Posted:
2021-10-12
First Post:
2011-09-16
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)
Sponsor:
Bristol-Myers Squibb
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2011-12-16
Start Date Type:
ACTUAL
Primary Completion Date:
2016-07-20
Primary Completion Date Type:
ACTUAL
Completion Date:
2021-07-23
Completion Date Type:
ACTUAL
First Submit Date:
2011-09-16
First Submit QC Date:
None
Study First Post Date:
2011-10-18
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2017-12-19
Results First Submit QC Date:
None
Results First Post Date:
2019-08-05
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-09-20
Last Update Post Date:
2021-10-12
Last Update Post Date Type:
ACTUAL